Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AVEO and Astellas Discontinue Breast Cancer Trial

Published: Friday, January 31, 2014
Last Updated: Friday, January 31, 2014
Bookmark and Share
Joint decision to discontinue trial due to insufficient enrollment.

AVEO Oncology today  announced  that AVEO and Astellas Pharma Inc.  have jointly decided to discontinue the BATON ( Biomarker Assessment of Tivozanib in ONcology ) breast  cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO  previously announced that enrollment in this study had been slower than anticipated, and enrollment rates did not improve substantially following additional patient  recruitment efforts.  

“While we believe in the potential benefits of tivozanib for patients with triple  negative breast cancer, we have decided to discontinue the trial because of low patient  accrual,” stated William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO.  “We want to thank the study investigators and their patients who participated in the  trial for their support.” 

The BATON - BC study initiated patient enrollment in December 2012 in a  randomized, double - blind, multicenter Phase 2 clinical trial, evaluating the efficacy of  tivozanib in combination with paclitaxel compared to placebo in combination with  paclitaxel in patients with locally recurrent or metastatic  triple negative breast cancer  who have received no more than one systemic therapy for advanced or metastatic  breast cancer.  All  committed expenses related to the BATON - BC study are shared  equally  between AVEO and  Astellas.  

Separately, as announced in December 2013, data from a planned interim analysis of  the Phase 2 study of tivozanib in patients with colorectal cancer indicate that the study  is unlikely to meet the primary endpoint in the intent - to - treat patient population. Interim data  are being evaluated, and  AVEO and Astellas are in discussions regarding  next steps.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AVEO Initiates First Clinical Trial of Novel HGF Antagonist
AVEO initiates first clinical trial of novel HGF antagonist in patients with advanced solid tumors and lymphomas.
Wednesday, September 24, 2008
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!